Celsion

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Data show d ose - dependent suppression of immun e- suppressive agents

Results of Celsion's OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research

OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted

Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

vTv Therapeutics

Zosano Pharma

These three biotech penny stocks all have developed drugs that have shown strong indications of success. The post 3 Biopharma Penny Stocks That Could be Millionaire Makers appeared first on InvestorPlace.

3 Biopharma Penny Stocks That Could be Millionaire Makers

LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University's Phase I PanDox study with ThermoDox® in conjunction with Focused Ultrasound in patients with pancreatic cancer. ThermoDox® is Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.

Celsion GmbH Announces Commencement of Enrollment in Oxford University's Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer

Celsion GmbH will manage current and future cancer studies with Thermo D ox ®

Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

Improvement to the Balance Sheet Leverages Strong Equity Structure

Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?

Brings extensive biopharmaceutical legal background to the Board

Celsion Appoints Christine A. Pellizzari to its Board of Directors

25-year pharmaceutical industry executive brings broad drug development perspective

Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors

A Quorum Has Been Achieved t o Reconvene Annual Meeting on Thursday June 10, 2021

CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

Calls for All Shareholders to Vote so Quorum Requirement t o Hold The Meeting is Met

Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021

Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2021 Results - Earnings Call Transcript

Focus on Immuno-Oncology and  Next-Generation Vaccines is Suppor ted with a Strong Balance Sheet

Celsion Corporation Reports First Quarter 2021 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 10:00 a.m. EDT on Friday, May 14, 2021 to discuss financial results for the first quarter ended March 31, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines.

Celsion Corporation to Hold First Quarter 2021 Financial Results and Business Update Conference Call on Friday, May 14, 2021

LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management participated in Alliance Global Partners' (AGP) Virtual Series on April 21, 2021. Michael H. Tardugno, Chairman, President and Chief Executive Officer, and Kursheed Anwar, Ph.D., Executive Vice President and Chief Scientific Officer were interviewed in a “Fireside Chat” by Matt Cross, Senior Biotech Research Analyst at AGP. The discussion focused on the Company's lead product, GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer currently in Phase II studies, and on its PLACCINE vaccine development platform.

Celsion Management Participates in Alliance Global Partners Virtual Series

Ambow Education Holding Ltd - ADR

Digital Ally Inc

Penny stocks are in focus once again as the hype around Doge Coin ramps up The post Top Penny Stocks Today? 3 Cheap Stocks to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks Today? 3 Cheap Stocks to Watch

Lawrenceville, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net proceeds of $13.9 million, after deducting placement agents' fees but before expenses payable by the Company.

CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING

Celsion Corporation (NASDAQ: CLSN) has announced a poster highlighting its ongoing Phase 1/2 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting on Women's Cancer. GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy designed using TheraPlas, its proprietary, synthetic, non-viral nanoparticle delivery system platform.

Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates

Company reports further strengthening of R0 resection results in patients treated with GEN-1

Poster on Celsion Corporation's Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer

VirTra

Virtra Inc (NASDAQ: VTSI) shares are trading lower by 22% Wednesday after the company priced a registered direct offering at $6 per share. VirTra is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military and commercial uses.

Why VTSI Stock AND CLSN Stock Are Trading Lower Today

LAWRENCEVILLE, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 shares of its common stock at a purchase price of $1.30 per share in a registered direct offering, for gross proceeds of $15 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 5, 2021, subject to the satisfaction of customary closing conditions.

CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING

Celsion Corporation (CLSN) CEO Michael Tardugno on Q4 2020 Results - Earnings Call Transcript

Entered 2021 with a Focus on Cancer Immunotherapy and  Next-Generation Infectious Vaccines and a Strong Balance Sheet

Celsion Corporation Reports 2020 Financial Results and Provides Business Update

FedEx

NIKE

Luminar Technologies

Wednesday afternoon's and Thursday morning's noteworthy earnings reports were included in our Tuesday preview covering scheduled reports from electric pickup maker Lordstown Motors, cannabis producers Sundial Growers and Hexo, and discount retailer Dollar General.

Earnings Previews: FedEx, Luminar, Nike, Celsion

LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Friday, March 19, 2021 to discuss financial results for the year ended December 31, 2020 and provide an update on clinical development programs with GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin under investigator-sponsored development for several cancer indications. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines. The Company's immunotherapy candidate, GEN-1, is currently in Phase II development for the localized treatment of advanced ovarian cancer.

News for Celsion Stock (CLSN)